Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179124 | 1.00 | ESR1 (0.46) | ESR1ESR2HDAC1KDM2BGPR119 | |
| SCHEMBL3171918 | 0.86 | ESR1 (0.43) | ESR1ESR2HDAC1KDM2BGPR119 | |
| SCHEMBL3171912 | 0.86 | ESR1 (0.43) | ESR1ESR2HDAC1KDM2BGPR119 | |
| SCHEMBL3189285 | 0.85 | ESR1 (0.43) | ESR1ESR2HDAC1KDM2BGPR119 | |
| SCHEMBL3189272 | 0.85 | ESR1 (0.43) | ESR1ESR2HDAC1KDM2BGPR119 | |
| SCHEMBL3181100 | 0.77 | ESR1 (0.46) | ESR1ESR2KDM2BGPR119 | |
| SCHEMBL3178592 | 0.76 | GPR119 (0.55) | ESR1ESR2GPR119ABHD6 | |
| SCHEMBL3181247 | 0.76 | ESR1 (0.47) | ESR1ESR2KDM2BGPR119 | |
| SCHEMBL3176556 | 0.76 | GPR119 (0.54) | GPR119 | |
| SCHEMBL3188465 | 0.76 | MOGAT2 (0.45) | ESR1ESR2KDM2BGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | claimed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | ESR1 638/4885ESR2 218/4885HDAC1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.